Literature DB >> 9446802

A new death receptor 3 isoform: expression in human lymphoid cell lines and non-Hodgkin's lymphomas.

K Warzocha1, P Ribeiro, C Charlot, N Renard, B Coiffier, G Salles.   

Abstract

Two isoforms encoding the full-length transmembrane death receptor 3 (DR3) were isolated from mRNAs of a panel of human cell lines and tumor tissues obtained from patients with follicular non-Hodgkin's lymphoma. A new DR3 variant (DR3 beta) was characterized by 2 insertions of respectively 20- and 7-base pairs (bp) which result in a predictive translated polypeptide differing from the described DR3 molecule by a 28 amino-acid stretch in the extracellular domain. DR3 was shown to be expressed in all cell lines and lymphoma samples tested, whereas DR3 beta expression was restricted to lymphoid T-cell and immature B-cell lines and to selected cases with follicular lymphoma. These data provide new insight into the molecular heterogeneity of DR3, suggesting the presence of several receptor isoforms that can participate in lymphoid cell homeostasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9446802     DOI: 10.1006/bbrc.1997.7948

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  DR3 regulates negative selection during thymocyte development.

Authors:  E C Wang; A Thern; A Denzel; J Kitson; S N Farrow; M J Owen
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

2.  Mouse receptor interacting protein 3 does not contain a caspase-recruiting or a death domain but induces apoptosis and activates NF-kappaB.

Authors:  N J Pazdernik; D B Donner; M G Goebl; M A Harrington
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

3.  Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.

Authors:  Zhicheng Ge; Andrew J Sanders; Lin Ye; Wen G Jiang
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

4.  Expression of silencer of death domains and death-receptor-3 in normal human kidney and in rejecting renal transplants.

Authors:  Rafia S Al-Lamki; Jun Wang; Sathia Thiru; Nicholas R Pritchard; J Andrew Bradley; Jordan S Pober; John R Bradley
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 5.  Immunobiology of TNFSF15 and TNFRSF25.

Authors:  Taylor H Schreiber; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

6.  Survival advantages conferred to colon cancer cells by E-selectin-induced activation of the PI3K-NFκB survival axis downstream of Death receptor-3.

Authors:  Nicolas Porquet; Andrée Poirier; François Houle; Anne-Laure Pin; Stéphanie Gout; Pierre-Luc Tremblay; Eric R Paquet; Roscoe Klinck; François A Auger; Jacques Huot
Journal:  BMC Cancer       Date:  2011-07-01       Impact factor: 4.430

Review 7.  The role of TL1A and DR3 in autoimmune and inflammatory diseases.

Authors:  Yoshihiro Aiba; Minoru Nakamura
Journal:  Mediators Inflamm       Date:  2013-12-21       Impact factor: 4.711

8.  TL1-A can engage death receptor-3 and activate NF-kappa B in endothelial cells.

Authors:  Jun Wang; Rafia S Al-Lamki; Xinwang Zhu; Hanzhe Liu; Jordan S Pober; John R Bradley
Journal:  BMC Nephrol       Date:  2014-11-16       Impact factor: 2.388

9.  The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells.

Authors:  You Cheng Zhang; Liu Qing Guo; Xiao Chen; Gen Nian Wang; Ri Ni; Man Cai Wang; Feng Xian Wei
Journal:  Mol Med Rep       Date:  2014-11-04       Impact factor: 2.952

10.  Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation.

Authors:  Lei Fang; Becky Adkins; Vadim Deyev; Eckhard R Podack
Journal:  J Exp Med       Date:  2008-04-14       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.